Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension.

Li Q, Barrett A, Vijayakrishnan B, Tiberghien A, Beard R, Rickert KW, Allen KL, Christie RJ, Marelli M, Harper J, Howard P, Wu H, Dall'Acqua WF, Tsui P, Gao C, Borrok MJ.

Bioconjug Chem. 2019 Apr 17;30(4):1232-1243. doi: 10.1021/acs.bioconjchem.9b00170. Epub 2019 Apr 3.

PMID:
30912649
2.

Functional mimetic of the G-protein coupled receptor CXCR4 on a soluble antibody scaffold.

Koksal AC, Pennini ME, Marelli M, Xiao X, Dall'Acqua WF.

MAbs. 2019 May/Jun;11(4):725-734. doi: 10.1080/19420862.2019.1596703. Epub 2019 Apr 16.

PMID:
30900513
3.

Targeted drug delivery via caveolae-associated protein PV1 improves lung fibrosis.

Marchetti GM, Burwell TJ, Peterson NC, Cann JA, Hanna RN, Li Q, Ongstad EL, Boyd JT, Kennedy MA, Zhao W, Rickert KW, Grimsby JS, Dall'Acqua WF, Wu H, Tsui P, Borrok MJ, Gupta R.

Commun Biol. 2019 Mar 7;2:92. doi: 10.1038/s42003-019-0337-2. eCollection 2019.

4.

Tag-on-Demand: exploiting amber codon suppression technology for the enrichment of high-expressing membrane protein cell lines.

Britton ZT, London TB, Carrell J, Dosanjh B, Wilkinson T, Bowen MA, Wu H, Dall'Acqua WF, Marelli M, Mazor Y.

Protein Eng Des Sel. 2018 Oct 1;31(10):389-398. doi: 10.1093/protein/gzy032.

PMID:
30753634
5.

Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategy.

Varkey R, Du Q, Karnell JL, Xiao X, Casey KA, Woods R, Rosenthal K, Wilson S, Dall'Acqua WF, Wu H, Herbst R, Ettinger R, Damschroder M.

PLoS One. 2019 Jan 25;14(1):e0211236. doi: 10.1371/journal.pone.0211236. eCollection 2019.

6.

Amber suppression coupled with inducible surface display identifies cells with high recombinant protein productivity.

Chakrabarti L, Zhuang L, Roy G, Bowen MA, Dall'Acqua WF, Hawley-Nelson P, Marelli M.

Biotechnol Bioeng. 2019 Apr;116(4):793-804. doi: 10.1002/bit.26892. Epub 2019 Jan 18.

7.

Enhancing IgG distribution to lung mucosal tissue improves protective effect of anti-Pseudomonas aeruginosa antibodies.

Borrok MJ, DiGiandomenico A, Beyaz N, Marchetti GM, Barnes AS, Lekstrom KJ, Phipps SS, McCarthy MP, Wu H, Dall'Acqua WF, Tsui P, Gupta R.

JCI Insight. 2018 Jun 21;3(12). pii: 97844. doi: 10.1172/jci.insight.97844. eCollection 2018 Jun 21.

8.

Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport.

Li Q, White JB, Peterson NC, Rickert KW, Lloyd CO, Allen KL, Rosenthal K, Gao X, Wu H, Dall'Acqua WF, Borrok MJ, Tsui P.

J Control Release. 2018 Jun 10;279:126-135. doi: 10.1016/j.jconrel.2018.04.013. Epub 2018 Apr 11.

PMID:
29653224
9.

A high-throughput platform for population reformatting and mammalian expression of phage display libraries to enable functional screening as full-length IgG.

Xiao X, Douthwaite JA, Chen Y, Kemp B, Kidd S, Percival-Alwyn J, Smith A, Goode K, Swerdlow B, Lowe D, Wu H, Dall'Acqua WF, Chowdhury PS.

MAbs. 2017 Aug/Sep;9(6):996-1006. doi: 10.1080/19420862.2017.1337617. Epub 2017 Jun 14.

10.

Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA.

Wang Q, Chen Y, Cvitkovic R, Pennini ME, Chang CS, Pelletier M, Bonnell J, Koksal AC, Wu H, Dall'Acqua WF, Stover CK, Xiao X.

PLoS One. 2017 Jan 20;12(1):e0170529. doi: 10.1371/journal.pone.0170529. eCollection 2017.

11.

Enhancement of antibody functions through Fc multiplications.

Wang Q, Chen Y, Pelletier M, Cvitkovic R, Bonnell J, Chang CY, Koksal AC, O'Connor E, Gao X, Yu XQ, Wu H, Stover CK, Dall'Acqua WF, Xiao X.

MAbs. 2017 Apr;9(3):393-403. doi: 10.1080/19420862.2017.1281505. Epub 2017 Jan 19.

12.

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.

Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, Wu H, Dall'Acqua WF.

Sci Rep. 2017 Jan 9;7:40098. doi: 10.1038/srep40098.

13.

An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.

Borrok MJ, Mody N, Lu X, Kuhn ML, Wu H, Dall'Acqua WF, Tsui P.

J Pharm Sci. 2017 Apr;106(4):1008-1017. doi: 10.1016/j.xphs.2016.12.023. Epub 2017 Jan 3.

PMID:
28057542
14.

Molecular basis for the mechanism of action of an anti-TACE antibody.

Peng L, Cook K, Xu L, Cheng L, Damschroder M, Gao C, Wu H, Dall'Acqua WF.

MAbs. 2016 Nov/Dec;8(8):1598-1605. Epub 2016 Sep 9.

15.

Generation and Characterization of an IgG4 Monomeric Fc Platform.

Shan L, Colazet M, Rosenthal KL, Yu XQ, Bee JS, Ferguson A, Damschroder MM, Wu H, Dall'Acqua WF, Tsui P, Oganesyan V.

PLoS One. 2016 Aug 1;11(8):e0160345. doi: 10.1371/journal.pone.0160345. eCollection 2016.

16.

Immunotherapies against antibiotics-resistant Klebsiella pneumoniae.

Xiao X, Wu H, Dall'Acqua WF.

Hum Vaccin Immunother. 2016 Dec;12(12):3097-3098. doi: 10.1080/21645515.2016.1210746. Epub 2016 Jul 18. No abstract available.

17.

Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen.

Mazor Y, Yang C, Borrok MJ, Ayriss J, Aherne K, Wu H, Dall'Acqua WF.

PLoS One. 2016 Jun 20;11(6):e0157788. doi: 10.1371/journal.pone.0157788. eCollection 2016.

18.

A novel antibody discovery platform identifies anti-influenza A broadly neutralizing antibodies from human memory B cells.

Xiao X, Chen Y, Varkey R, Kallewaard N, Koksal AC, Zhu Q, Wu H, Chowdhury PS, Dall'Acqua WF.

MAbs. 2016 Jul;8(5):916-27. doi: 10.1080/19420862.2016.1170263. Epub 2016 Apr 6.

19.

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.

Geoghegan JC, Diedrich G, Lu X, Rosenthal K, Sachsenmeier KF, Wu H, Dall'Acqua WF, Damschroder MM.

MAbs. 2016;8(3):454-67. doi: 10.1080/19420862.2016.1143182. Epub 2016 Feb 8.

20.

Target-Agnostic Identification of Functional Monoclonal Antibodies Against Klebsiella pneumoniae Multimeric MrkA Fimbrial Subunit.

Wang Q, Chang CS, Pennini M, Pelletier M, Rajan S, Zha J, Chen Y, Cvitkovic R, Sadowska A, Heidbrink Thompson J, Yu Lin H, Barnes A, Rickert K, Wilson S, Stover CK, Dall'Acqua WF, Chowdhury PS, Xiao X.

J Infect Dis. 2016 Jun 1;213(11):1800-8. doi: 10.1093/infdis/jiw021. Epub 2016 Jan 14.

PMID:
26768253
21.

Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding.

Oganesyan V, Mazor Y, Yang C, Cook KE, Woods RM, Ferguson A, Bowen MA, Martin T, Zhu J, Wu H, Dall'Acqua WF.

Acta Crystallogr D Biol Crystallogr. 2015 Nov;71(Pt 11):2354-61. doi: 10.1107/S1399004715018015. Epub 2015 Oct 31.

22.

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody.

Peng L, Damschroder MM, Cook KE, Wu H, Dall'Acqua WF.

MAbs. 2016;8(1):163-75. doi: 10.1080/19420862.2015.1113359.

23.

Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.

Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P.

MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570.

24.

Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab.

Oganesyan V, Peng L, Woods RM, Wu H, Dall'Acqua WF.

J Biol Chem. 2015 Jun 12;290(24):14979-85. doi: 10.1074/jbc.M115.652156. Epub 2015 Apr 29.

25.

Insights into the molecular basis of a bispecific antibody's target selectivity.

Mazor Y, Hansen A, Yang C, Chowdhury PS, Wang J, Stephens G, Wu H, Dall'Acqua WF.

MAbs. 2015;7(3):461-9. doi: 10.1080/19420862.2015.1022695.

26.

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody.

Peng L, Oganesyan V, Wu H, Dall'Acqua WF, Damschroder MM.

MAbs. 2015;7(2):428-39. doi: 10.1080/19420862.2015.1007810.

27.

pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.

Borrok MJ, Wu Y, Beyaz N, Yu XQ, Oganesyan V, Dall'Acqua WF, Tsui P.

J Biol Chem. 2015 Feb 13;290(7):4282-90. doi: 10.1074/jbc.M114.603712. Epub 2014 Dec 23.

28.

Bi-epitope SPR surfaces: a solution to develop robust immunoassays.

Peng L, Damschroder MM, Wu H, Dall'Acqua WF.

PLoS One. 2014 Nov 5;9(11):e112070. doi: 10.1371/journal.pone.0112070. eCollection 2014.

29.

Mechanisms of neutralization of a human anti-α-toxin antibody.

Oganesyan V, Peng L, Damschroder MM, Cheng L, Sadowska A, Tkaczyk C, Sellman BR, Wu H, Dall'Acqua WF.

J Biol Chem. 2014 Oct 24;289(43):29874-80. doi: 10.1074/jbc.M114.601328. Epub 2014 Sep 10.

30.

Structural insights into neonatal Fc receptor-based recycling mechanisms.

Oganesyan V, Damschroder MM, Cook KE, Li Q, Gao C, Wu H, Dall'Acqua WF.

J Biol Chem. 2014 Mar 14;289(11):7812-24. doi: 10.1074/jbc.M113.537563. Epub 2014 Jan 27.

31.

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.

Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP.

Antimicrob Agents Chemother. 2013 Dec;57(12):6147-53. doi: 10.1128/AAC.01285-13. Epub 2013 Sep 30.

32.

Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-alpha toxin antibody fragment and alpha toxin.

Oganesyan V, Barnes A, Tkaczyk C, Ferguson A, Wu H, Dall'Acqua WF.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013 Mar 1;69(Pt 3):302-5. doi: 10.1107/S1744309113002881. Epub 2013 Feb 23.

33.

Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody.

Peng L, Oganesyan V, Damschroder MM, Wu H, Dall'Acqua WF.

J Mol Biol. 2011 Oct 21;413(2):390-405. doi: 10.1016/j.jmb.2011.08.018. Epub 2011 Aug 16.

PMID:
21867711
34.

Crystallization and preliminary X-ray diffraction analysis of the complex of a human anti-ephrin type-A receptor 2 antibody fragment and its cognate antigen.

Oganesyan V, Damschroder MM, Phipps S, Wilson SD, Cook KE, Wu H, Dall'Acqua WF.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Jun 1;66(Pt 6):730-3. doi: 10.1107/S1744309110015861. Epub 2010 May 29.

35.

Structural characterization of a human Fc fragment engineered for extended serum half-life.

Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall'acqua WF.

Mol Immunol. 2009 May;46(8-9):1750-5. doi: 10.1016/j.molimm.2009.01.026. Epub 2009 Feb 27.

PMID:
19250681
36.

Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon alpha-2A.

Oganesyan V, Damschroder MM, Cook KE, Wu H, Dall'Acqua WF.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Jan 1;65(Pt 1):14-6. doi: 10.1107/S1744309108037925. Epub 2008 Dec 25.

37.

Structural characterization of a human Fc fragment engineered for lack of effector functions.

Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF.

Acta Crystallogr D Biol Crystallogr. 2008 Jun;64(Pt 6):700-4. doi: 10.1107/S0907444908007877. Epub 2008 May 14.

38.

Structural characterization of a mutated, ADCC-enhanced human Fc fragment.

Oganesyan V, Damschroder MM, Leach W, Wu H, Dall'Acqua WF.

Mol Immunol. 2008 Apr;45(7):1872-82.

PMID:
18078997
39.

Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties.

Damschroder MM, Widjaja L, Gill PS, Krasnoperov V, Jiang W, Dall'Acqua WF, Wu H.

Mol Immunol. 2007 Apr;44(11):3049-60. Epub 2007 Jan 22.

PMID:
17241664
40.

Modulation of the effector functions of a human IgG1 through engineering of its hinge region.

Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H.

J Immunol. 2006 Jul 15;177(2):1129-38.

41.

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

Dall'Acqua WF, Kiener PA, Wu H.

J Biol Chem. 2006 Aug 18;281(33):23514-24. Epub 2006 Jun 21.

42.

Antibody humanization by framework shuffling.

Dall'Acqua WF, Damschroder MM, Zhang J, Woods RM, Widjaja L, Yu J, Wu H.

Methods. 2005 May;36(1):43-60.

PMID:
15848074
43.

Humanized antibodies and their applications.

Wu H, Dall'Acqua WF.

Methods. 2005 May;36(1):1-2. No abstract available.

PMID:
15848069
44.

Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies.

Damschroder MM, Kozhich AA, Woods RM, Cheng L, Mullikin BA, Wilson SD, Ulbrandt ND, Bachy CM, Wu H, Suzich JA, Kiener PA, Dall'Acqua WF, White WI.

Mol Immunol. 2004 Aug;41(10):985-1000.

PMID:
15302161
45.

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S.

J Immunol. 2002 Nov 1;169(9):5171-80.

Supplemental Content

Loading ...
Support Center